Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Positive Non-small Cell Lung Cancer Patients

First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Positive... NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation Positive Non-small Cell Lung Cancer Patients Lecia V. Sequist, MD, MPH 2– 4,12 smoking, female sex, and East Asian ethnicity. This sce- Small molecule tyrosine kinase inhibitors of the epidermal growth nario, an identifiable molecular marker that predicts a marked factor receptor (EGFR) are important agents in the treatment of differential response to a given therapy, is an ideal one for non-small cell lung cancer (NSCLC) and have enhanced activity in testing the promise of genotype-directed therapy. The geno- the subpopulation of patients with NSCLC who harbor somatic type-directed strategy aims to abandon the traditional clinical activating mutations of the EGFR gene. This review summarizes the oncology approach of treating all patients with the same data describing the use of EGFR tyrosine kinase inhibitors in a histologic diagnosis under the same treatment algorithm in genotype-directed population of NSCLC patients with EGFR muta- favor of a more specific molecular analysis at the time of tions and discusses areas that require further study. diagnosis that has the power to elucidate optimal therapies for Key Words: Non-small cell lung cancer, Epidermal growth factor http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Positive Non-small Cell Lung Cancer Patients

Journal of Thoracic Oncology , Volume 3 – Jun 1, 2008

Loading next page...
 
/lp/wolters-kluwer-health/first-generation-epidermal-growth-factor-receptor-tyrosine-kinase-xNWFzBCazN

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation Positive Non-small Cell Lung Cancer Patients Lecia V. Sequist, MD, MPH 2– 4,12 smoking, female sex, and East Asian ethnicity. This sce- Small molecule tyrosine kinase inhibitors of the epidermal growth nario, an identifiable molecular marker that predicts a marked factor receptor (EGFR) are important agents in the treatment of differential response to a given therapy, is an ideal one for non-small cell lung cancer (NSCLC) and have enhanced activity in testing the promise of genotype-directed therapy. The geno- the subpopulation of patients with NSCLC who harbor somatic type-directed strategy aims to abandon the traditional clinical activating mutations of the EGFR gene. This review summarizes the oncology approach of treating all patients with the same data describing the use of EGFR tyrosine kinase inhibitors in a histologic diagnosis under the same treatment algorithm in genotype-directed population of NSCLC patients with EGFR muta- favor of a more specific molecular analysis at the time of tions and discusses areas that require further study. diagnosis that has the power to elucidate optimal therapies for Key Words: Non-small cell lung cancer, Epidermal growth factor

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Jun 1, 2008

There are no references for this article.